Target immunotherapy of atopic dermatitis



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The data about novel immunopathogenetic mechanisms of AD that may be a therapeutic targets for the new immune therapy are presented in the review. The current results of modern clinical trials of targeted biological agents in AD are summarized.

Full Text

Restricted Access

About the authors

O G Elisyutina

NRC Institute of Immunology FMBA ofRussia

Email: El-olga@yandex.ru

References

  1. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67:1475-1482. doi: 10.1111/all.12049.
  2. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner Gelmetti C et al. Guidelines for treatment of atopic eczema (atopic dermatitis). Part I. J Eur Acad Dermatol Venereol. 2012;26:1045-1060. doi: 10.1111/j.1468-3083.2012.04636.x.
  3. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;71:338-351. doi: 10.1016/j.jaad.2014.03.030.
  4. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:118-127.
  5. Schneider L, Hanifin J, Boguniewicz M, Eichenfield LF, Spergel JM, Dakovic R, Paller AS. Study ofthe Atopic March: Development of Atopic Comorbidities. Pediatr Dermatol. 2016;33:388-398. doi: 10.1111/pde.12867.
  6. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134:769-779. doi: 10.1016/j.jaci.2014.08.008.
  7. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner Deleuran M, Gelmetti C et al. Guidelines for treatment of atopic eczema (atopic dermatitis). Part II. J Eur Acad Dermatol Venereol. 2012;26:1176-1193. doi: 10.1111/j.1468-3083.2012.04635.x.
  8. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327-349. doi: 10.1016/j.jaad.2014.03.030.
  9. Cabanillas B, Brehler AC, Novak N. Atopic dermatitis phenotypes and the need for personalized medicine. Curr Opin Allergy Clin Immunol. 2017;17:309-315. DOI: 10.1097/ ACI.0000000000000376.
  10. Beyer K, Nickel R, Freidhoff L, Bjôrkstén B, Huang SK, Barnes KC et al. Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. J Invest Dermatol. 2000;115:906-908. doi: 10.1046/j.1523-1747.2000.00096.x.
  11. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med. 1997;337:1720-1725.
  12. Deichmann KA, Heinzmann A, Forster J, Dischinger S, Mehl C, Brueggenolte E, Hildebrandt F, Moseler M, Kuehr J. Linkage and allelic association of atopy and markers flanking the IL4-receptor gene. Clin Exp Allergy. 1998;28:151-155.
  13. Wu Z1, Qin W, Zeng J, Huang C, Lu Y Li S. Association Between IL-4 Polymorphisms and Risk of Liver Disease: An Updated Meta-Analysis. Medicine (Baltimore). 2015;94(35):e1435. doi: 10.1097/MD.0000000000001435.
  14. Roesner LM, Heratizadeh A, Begemann G, Kienlin P, Hradetzky S, Niebuhr M et al. Der p 1 and Der p 2-Specific T-Cells Display a Th2, Th17, and Th2/Th17 Phenotype in Atopic Dermatitis. J Invest Dermatol. 2015;135: 2324-2327. doi: 10.1038/jid.2015.
  15. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124:R7-R12. doi: 10.1016/j.jaci.2009.07.012.
  16. Narozna B, Hoffmann A, Sobkowiak P, Schoneich N, Brçborowicz A, Szczepankiewicz A. Polymorphisms in the interleukin 4, interleukin 4 receptor and interleukin 13 genes and allergic phenotype: A case control study. Adv Med Sci. 2016;61:40-45. doi: 10.1016/j.advms.2015.07.003.
  17. Lee E, Lee SH, Kwon JW, Kim YH, Cho HJ, Yang SI et al. Atopic dermatitis phenotype with early onset and high serum IL-13 is linked to the new development of bronchial hyperresponsiveness in school children. Allergy. 2016;71:692-700. doi: 10.1111/all.12844.
  18. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130-139. doi: 10.1056/NEJMoa1314768.
  19. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335-2348. doi: 10.1056/NEJMoa1610020.
  20. Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387:40-52. doi: 10.1016/S0140-6736(15)00388-8.
  21. Han Y, Chen Y, Liu X, Zhang J, Su H, Wen H et al. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2017;140:888-891. DOI: 10.1016/j. jaci.2017.04.015.
  22. Jancin В. Lebrikizumab opens new door in atopic dermatitis therapy. http://www.mdedge.com/edermatolo-gynews/article/115736/atopic-dermatitis/lebrikizum-ab-opens-new-door-atopic-dermatitis. Cited 12 Feb 2017.
  23. Phase 2 study to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis. Study results. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/ results/NCT02347176?sect=X70156&cond=tralokinum-ab&draw=1&rank=7#outcome1 Cited 11 Aug 2017.
  24. Otsuka A, Kabashima K. Mast cells and basophils in cutaneous immune responses. Allergy. 2015;70:131-140. DOI: 10.1111/ all.12526.
  25. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17-cells for atopic dermatitis. J Invest Dermatol. 2008;128:2625-2630. DOI: 10.1038/ jid.2008.111.
  26. Noda S, Suarez-Farinas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136:1254-1264. doi: 10.1016/j.jaci.2015.08.015.
  27. Suarez-Farinas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132:361-370. doi: 10.1016/j.jaci.2013.04.046.
  28. Pariser D, Frankel E, Schlessinger J, Poulin Y, Vender R, Langley RG et al. Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. 2017 Dec 7. doi: 10.1007/s13555-017-0211-4. [Epub ahead of print.]
  29. Heratizadeh A, Werfel T. Anti-inflammatory therapies in atopic dermatitis. Allergy. 2016;71:1666-1675. DOI: 10.1111/ all.13065.
  30. Gangemi S, Quartuccio S, Casciaro M, Trapani G, Minciullo PL, Imbalzano E. Interleukin 31 and skin diseases: A systematic review. Allergy Asthma Proc. 2017;38:401-408. doi: 10.2500/aap.2017.38.4080.
  31. Kanda N, Hau CS, Tada Y, Sato S, Watanabe S. Decreased serum LL-37 and vitamin D3 levels in atopic dermatitis: relationship between IL-31 and oncostatin M. Allergy. 2012;67:804-812. doi: 10.1111/j.1398-9995.2012.02824.x.
  32. Schulz F, Marenholz I, Fölster-Holst R, Chen C, Sternjak A, Baumgrass R et al. A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol. 2007;120:1097-1102. doi: 10.1016/j.jaci.2007.07.065.
  33. Niebuhr M, Mamerow D, Heratizadeh A, Satzger I, Werfel T Staphylococcal alpha-toxin induces a higher T-cell proliferation and interleukin-31 in atopic dermatitis. Int Arch Allergy Immunol. 2011;156:412-415. doi: 10.1159/000323905.
  34. Cornelissen C, Marquardt Y, Czaja K, Wenzel J, Frank J, Luscher-Firzlaff J et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol. 2012;129:426-433. DOI: 10.1016/j. jaci.2011.10.042.
  35. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376:826-835. doi: 10.1056/NEJMoa1606490.
  36. Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174:296-304. doi: 10.1111/bjd.14207.
  37. Boyman O, Kaegi C, Akdis M, Bavbek S, Bossios A, Chatzipetrou A et al. EAACI IG Biologicals task force paper on the use ofbiologic agents in allergic disorders. Allergy. 2015;70:727-754.
  38. Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162(1):137-146. doi: 10.1111/j.1365-2133.2009.09491.x.
  39. Zaghi D, Krueger GG, Callis Duffin K. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. J Drugs Dermatol. 2012;11:160-167.
  40. Agusti-Mejias A, Messeguer F, Garcia R, Febrer I. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol. 2013;25:368-370. doi: 10.5021/ad.2013.25.3.368.
  41. Wlodek C, Hewitt H, Kennedy CT. Use of ustekinumab for severe refractory atopic dermatitis in a young teenager. Clin Exp Dermatol. 2016;41:625-627. doi: 10.1111/ced.12847.
  42. Samorano LP, Hanifin JM, Simpson EL, Leshem YA. Inadequate response to ustekinumab in atopic dermatitis - a report of two patients. J Eur Acad Dermatol Venereol. 2016;30:522-523. doi: 10.1111/jdv.12918.
  43. Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2017;26:28-35. doi: 10.1111/exd.13112.
  44. Zhou J, Zhou Y, Lin LH, Wang J, Peng X, Li J et al. Association of polymorphisms in the promoter region of FCER1A gene with atopic dermatitis, chronic uticaria, asthma, and serum immunoglobulin E levels in a Han Chinese population. Hum Immunol. 2012;73:301-305. DOI: 10.1016/j. humimm.2011.12.001.
  45. Weidinger S, Gieger C, Rodriguez E, Baurecht H, Mempel M, Klopp N et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. PLoS Genet. 2008;4(8). Available at: e1000166. doi: 10.1371/journal. pgen.1000166.
  46. Liang Y, Wang P, Zhao M, Liang G, Yin H, Zhang G et al. Demethylation of the FCER1G promoter leads to FcepsilonRI overexpression on monocytes of patients with atopic dermatitis. Allergy. 2012;67:424-430. doi: 10.1111/j.1398-9995.2011.02760.x.
  47. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci. 2010;58:1-7. doi: 10.1016/j.jderms-ci.2010.02.008.
  48. Fukiwake N, Furusyo N, Takeoka H, Toyoda K, Kubo N, Kido M, Hayashida S, Uchi H, Moroi Y, Urabe K, Kinukawa N, Nose Y Hayashi J, Furue M. Association factors for atopic dermatitis in nursery school children in Ishigaki islands - Kyushu University Ishigaki Atopic Dermatitis Study (KIDS). Eur J Dermatol. 2008;18:571-574. doi: 10.1684/ejd.2008.0479.
  49. Katoh N, Hirano S, Kishimoto S. Prognostic factor of adult patients with atopic dermatitis. J Dermatol. 2008;35:477-483. doi: 10.1111/j.1346-8138.2008.00507.x.
  50. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005;53:338-340. doi: 10.1016/j.jaad.2005.02.014.
  51. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007;120:1223-1225. doi: 10.1016/j.jaci.2007.08.060.
  52. Hotze M, Baurecht H, Rodriguez E, Chapman-Rothe N, Ollert M, Folster-Holst R et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy. 2014;69:132-135. doi: 10.1111/all.12234.
  53. Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008;121:122-128. DOI: 10.1016/j. urolonc.2013.08.018.
  54. Nakajima S, Igyarto BZ, Honda T, Egawa G, Otsuka A, Hara-Chikuma M et al. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. J Allergy Clin Immunol. 2012;129:1048-1055. doi: 10.1016/j.jaci.2012.01.063.
  55. Mizutani N, Sae-Wong C, Kangsanant S, Nabe T, Yoshino S. Thymic stromal lymphopoietin-induced interleukin-17A is involved in the development of IgE-mediated atopic dermatitis-like skin lesions in mice. Immunology. 2015;146:568-581. doi: 10.1111/imm.12528.
  56. Tidwell WJ, Fowler JF Jr. J Am Acad Dermatol. T-Cell Inhibitors for Atopic Dermatitis. 2017 Dec 14. pii: S0190-9622(17)32821-9. doi: 10.1016/j.jaad.2017.12.020. [Epub ahead of print.]
  57. Bao L, Zhang H, Chan LS. The involvement of the JAKSTAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2:e24137. DOI: 10.4161/ jkst.24137.
  58. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134:2988-2990. doi: 10.1016/j.jaad.2017.10.046.
  59. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73:395-399. DOI: 10.1016/j. jaad.2015.06.045.
  60. Bissonnette R, Papp KA, Poulin Y Gooderham M, Raman M, Mallbris L et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175:902-911. doi: 10.1111/bjd.14871.
  61. Griffiths CE, Van Leent EJ, Gilbert M, Traulsen J, Cipamyflline Study G. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol. 2002;147:299-307.
  62. Paller AS, Tom WL, Lebwohl Mg, Blumenthal RL, Boguniewicz M, Call RS et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75:494-503. doi: 10.1016/j.jaad.2016.05.046.
  63. Ohba F, Matsuki S, Imayama S, Matsuguma K, Hojo S, Nomoto M et al. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: an investigator-blinded, vehicle-controlled study. J Dermatolog Treat. 2016;27:467-472. doi: 10.3109/09546634.2016.1157257.
  64. Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148:890-897. doi: 10.1001/archdermatol.2012.812.
  65. Volf EM, Au SC, Dumont N, Scheinman P, Gottlieb AB. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11:341-346.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2018



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies